Value-Based HIV Formularies

Optimizing Use of Clinical Evidence & Pharmacoeconomic Models in Managed Care

Meeting Slides

Clinical Practice Guidelines

Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living With HIV.

US Department of Health and Human Services, 2017.

US Public Health Service: Preexposure Prophylaxis for the Prevention of HIV Infection in the United States—2014. A Clinical Practice Guideline.

Centers for Disease Control and Prevention, 2014.

Clinical Resources

AMCP Format for Formulary Submissions. Version 3.1.

Academy of Managed Care Pharmacy, 2012.

The Sourcebook: Essentials of Health Policy. Chapter 5: Health Care Costs.

Alliance for Health Policy Web Site, 2017.

HIV Cost-effectiveness.

Centers for Disease Control and Prevention, 2017.

Suggested Readings

AMCP Partnership Forum: enabling the exchange of clinical and economic information pre-FDA approval.

Academy of Managed Care Pharmacy. J Manag Care Pharm. 2017;23(1):105-112.

CMS to test enhanced medication therapy management model: aims for greater use of pharmacists, cost savings, and better outcomes.

Barlas S. P T. 2016;41(7):423-441.

The impact of comprehensive case management on HIV client outcomes.

Brennan-Ing M, et al. PLoS One. 2016;11(2):e0148865.

Assessment of the level of satisfaction and unmet data needs for specialty drug formulary decisions in the United States.

Choi Y, Navarro RP. J Manag Care Spec Pharm. 2016;22(4):368-375

Safety and efficacy of long-acting CAB and RPV as two drug IM maintenance therapy: LATTE-2 week 96 results.

Eron J, et al. 9th International Antiviral Society Conference on HIV Science. July 23−26, 2017; Paris, France. Abstract MOAX0205LB.

Expenditures for persons living with HIV enrolled in Medicaid, 2006-2010.

Fleishman JA, et al. J Acquir Immune Defic Syndr. 2016;72(4):408-415.

A phase 3 randomized controlled clinical trial of bictegravir in a fixed dose combination, B/F/TAF, vs ABC/DTG/3TC in treatment-naïve adults at week 48.

Gallant J, et al. 9th International Antiviral Society Conference on HIV Science. July 23−26, 2017; Paris, France. Abstract MOAB0105LB.

What are the incentives for Medicare prescription drug plans to consider long-term outcomes and cost?

Hung A, Perfetto EM. J Manag Care Spec Pharm. 2016;22(7):773-778.

A qualitative study of barriers to and facilitators of optimal engagement in care among PLWH and substance use/misuse.

Kuchinad KE, et al. BMC Res Notes. 2016;9:229.

Phase III Sword 1&2: switch to DTG+RPV maintains virologic suppression through 48 wks.

Lllibre JM, et al. 24th Conference on Retroviruses and Opportunistic Infections; February 13−16, 2017; Seattle, WA. Abstract 44LB.

The role of pharmacoeconomic modeling in evidence-based and value-based formulary guidelines.

Malone DC. J Manag Care Pharm. 2005;11(suppl 4):S7-S10.

Demographic, insurance, and health characteristics of newly enrolled HIV-positive patients after implementation of the Affordable Care Act in California.

Satre DD, et al. Am J Public Health. 2016;106(7):1211-1213.

Dual therapy with darunavir/ritonavir plus lamivudine for HIV-1 treatment initiation: week 24 results of the randomized ANDES study.

Sued O, et al. 9th International Antiviral Society Conference on HIV Science. July 23−26, 2017; Paris, France. Abstract MOAB0106LB.

Single- versus multiple-tablet HIV regimens: adherence and hospitalization risk.

Sutton SS, et al. Am J Manag Care. 2016;22(4):242-248.

Systemic market and organizational changes: impact on P&T committees.

Vogenberg FR, et al. P T. 2017;42(1):28-32.

Relevant Resources

PrEP for Your Patients’ Needs

The PCPs Role in Preventing HIV


Building Bridges to Reach People Who Inject Drugs With the Goal to Eliminate HCV

Targeting NASH

Advances in the Diagnosis and Treatment of Nonalcoholic Steatohepatitis